RAMQ Provides Open Access to DEXILANT, the First and only Proton Pump
Inhibitor (PPI) with a DUAL DELAYED RELEASE (DDR) Technology
MISSISSAUGA, ON, June 3, 2011 /CNW/ - Patients in Quebec living with
GERD now have open access to a new treatment option that offers improved and
sustained symptom relief, as the Régie de l'assurance maladie Quebec
(RAMQ) adds DEXILANT (dexlansoprazole) to the provincial formulary.
DEXILANT is the first and only proton pump inhibitor (PPI) with a novel
DUAL DELAYED RELEASE technology for the once-daily treatment of
heartburn associated with symptomatic non-erosive gastroesophageal
reflux disease (GERD), the healing of erosive esophagitis and the
maintenance of healed erosive esophagitis.
Quebec residents who qualify for Quebec's Public Prescription Drug
Insurance Plan - those 65 and older, recipients of last-resort
financial assistance and those who are not covered by private plans -
GERD is a chronic condition that affects approximately one-third of the
Canadian population and, if left untreated, can result in damage to the
esophagus leading to ulcers and bleeding.1,2 Some of the most common symptoms associated with GERD include:
regurgitation, sour taste in the mouth, pain or burning in the throat
or chest, and awakening in the night due to heartburn. Symptoms can be
triggered by foods, such as chocolate, fried/fatty foods, alcohol and
It is estimated that GERD sufferers are absent from work 16 per cent of
the year due to uncontrolled symptoms. In Canada, this represents 1.7
billion hours of lost productivity which amounts to $21 billion every
"Takeda is dedicated to developing health care solutions that address
the unmet medical needs of patients, and we are thrilled that Quebec
has recognized the needs of GERD patients," says Paul Friel, General
Manager and President, Takeda Canada, Inc. "By adding DEXILANT to the
provincial formulary, the province is not only helping more patients
gain access to this new treatment option, but helping these patients
get back to living better lives."
About Takeda Canada, Inc.
Takeda Canada, Inc. is a division of Takeda Pharmaceutical Company
Limited, the largest pharmaceutical company in Japan. The Canadian
headquarters was established in Mississauga, Ontario, in 2009. Takeda
Canada, Inc. currently distributes Actos® for the treatment of type 2
diabetes, DEXILANT for the treatment of gastroesophageal reflux disease
and ULORIC an innovative oral urate-lowering therapy to lower serum
uric acid levels in patients with gout. The company seeks to enhance
the lives of Canadians by providing innovative new products for
metabolic, cardiovascular, oncology, central nervous system, and other
related conditions. Takeda is committed to striving toward better
health for individuals and progress in medicine. To learn more about
Takeda Canada, Inc. visit www.takedacanada.com.
1 Canadian Digestive Health Foundation. GERD. http://www.cdhf.ca/pdfs/fact-sheets/CDHF_FactSheet_GERD.pdf#zoom=100. Accessed December, 2010.
2 Canadian Society of Intestinal Research. GERD. http://www.badgut.org/information-centre/gerd.html Accessed December, 2010.
SOURCE Takeda Canada, Inc.
For further information:
Takeda Canada, Inc.